Clinical Trials
24 trialsNCT06137144 2026-05-19
PRIMAVERA
AstraZeneca
Phase 1/2 Recruiting
NCT06035497 2026-05-01
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT07523555 2026-04-13
ADAPT-HEM
Beijing Biotech
Phase 1/2 Recruiting
NCT05255601 2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04390737 2026-01-30
Evaluate the Safety and Clinical Activity of HH2853
Haihe Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT06909877 2026-01-30
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Haihe Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT02264613 2026-01-13
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Aileron Therapeutics, Inc.
Phase 1/2 Completed
NCT04425070 2026-01-05
TOUCH
Antengene Corporation
Phase 1/2 Terminated
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT04105010 2025-04-04
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Dizal Pharmaceuticals
Phase 1/2 Completed
NCT05934513 2024-12-13
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Recruiting
NCT05269940 2024-11-13
A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies
Nanjing Zenshine Pharmaceuticals
Phase 1/2 Completed
NCT05749549 2024-08-07
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers
Shanghai Blueray Biopharma Co., Ltd.
Phase 1/2 Active not recruiting
NCT06173999 2024-05-14
A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT00888927 2024-04-25
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT05138458 2023-11-13
IMAGINE
Myeloid Therapeutics
Phase 1/2 Suspended
NCT02440685 2023-06-07
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
Phase 1/2 Terminated
NCT04444141 2022-10-19
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma
Akeso
Phase 1/2 Terminated
NCT00406809 2021-08-02
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
AbbVie
Phase 1/2 Completed
NCT03553914 2020-10-19
PLM60 for Peripheral T Cell Lymphoma (PTCL)
Conjupro Biotherapeutics, Inc.
Phase 1/2 Withdrawn
NCT00481871 2020-01-07
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT01456039 2019-02-11
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
Celgene
Phase 1/2 Completed
NCT02013362 2017-11-09
Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Mundipharma K.K.
Phase 1/2 Completed
NCT00724984 2014-04-07
PCYC-0403
Pharmacyclics LLC.
Phase 1/2 Completed